CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Reports Q4 revenue $17.8B, consensus $17.26B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of ...
Good day, everyone, and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief ...
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.